Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD).
Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.
John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.
In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.
The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.
Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.
Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.
Tardive dyskinesia (TD) has a real-world impact on patient lives. Greg Mattingly, MD, explores the social and emotional impact of TD on patients as well as its prevalence and diagnosis.
Formulate an approach to select the right treatment for patients with tardive dyskinesia.
Formulate an approach to diagnose patients with tardive dyskinesia.
This eCase explores diagnosis and treatment of tardive dyskinesia in an older female patient with a history of bipolar disorder.
Two expert faculty members discuss key articles in tardive dyskinesia research and the clinical implications, strengths, limitations, and salient conclusions.